Merck and Eisai, two leading pharmaceutical companies, have recently provided a sneak peek of their findings on the treatment of renal carcinoma. Renal carcinoma, also known as kidney cancer, is a type of cancer that starts in the cells of the kidney. It is one of the most common types of cancer, with an estimated 73,750 new cases and 14,830 deaths in the United States in 2020 alone.<\/p>\n
Merck and Eisai have been working together to develop a new treatment for renal carcinoma. The treatment is a combination of two drugs, lenvatinib and pembrolizumab. Lenvatinib is a type of drug called a tyrosine kinase inhibitor, which works by blocking the signals that cancer cells use to grow and divide. Pembrolizumab is a type of drug called an immune checkpoint inhibitor, which works by helping the body’s immune system to recognize and attack cancer cells.<\/p>\n
The two companies conducted a phase 3 clinical trial to test the effectiveness of the combination treatment. The trial involved 1,069 patients with advanced renal carcinoma who had not received any previous treatment. The patients were randomly assigned to receive either the combination treatment or sunitinib, which is a standard treatment for renal carcinoma.<\/p>\n
The results of the trial showed that the combination treatment was more effective than sunitinib in terms of overall survival and progression-free survival. Overall survival refers to the length of time that patients live after starting treatment, while progression-free survival refers to the length of time that patients live without their cancer getting worse.<\/p>\n
The combination treatment also had a better safety profile than sunitinib, with fewer side effects reported. The most common side effects of the combination treatment were hypertension, diarrhea, and fatigue.<\/p>\n
The findings of the trial are significant because they provide a new treatment option for patients with advanced renal carcinoma. The combination treatment has the potential to improve overall survival and progression-free survival, while also having a better safety profile than the standard treatment.<\/p>\n
Merck and Eisai plan to present the full results of the trial at an upcoming medical conference. The companies also plan to submit the combination treatment for regulatory approval in the United States and other countries.<\/p>\n
In conclusion, Merck and Eisai have provided a sneak peek of their findings on the treatment of renal carcinoma. The combination treatment of lenvatinib and pembrolizumab has shown promising results in a phase 3 clinical trial, with improved overall survival and progression-free survival and a better safety profile than the standard treatment. This new treatment option has the potential to improve outcomes for patients with advanced renal carcinoma.<\/p>\n
Merck and Eisai, two leading pharmaceutical companies, have recently provided a sneak peek of their findings on the treatment of renal carcinoma. Renal carcinoma, also known as kidney cancer, is a type of cancer that starts in the cells of the kidney. It is one of the most common types of cancer, with an estimated […]<\/p>\n","protected":false},"author":2,"featured_media":2527029,"menu_order":0,"template":"Default","format":"standard","meta":[],"aiwire-tag":[1146,436,1975,439,11,4766,17,132,18,5806,20,21,13556,790,5241,680,368,369,11333,6161,29,218,1946,11855,1174,9348,13191,2000,2001,144,2174,727,2336,2405,2059,686,156,10854,8509,8255,531,8019,5175,1785,1611,8537,3640,4517,50,1420,1629,242,55,288,1795,8462,13485,169,325,57,11832,479,60,61,29057,249,291,9380,4018,396,69,72,4619,179,75,78,183,331,184,5454,262,8555,5571,11399,2004,765,5,10,7,8,82,2749,701,3500,86,190,1089,3828,1359,91,356,11171,4625,1100,5838,1278,1821,496,706,2620,9482,3442,99,5581,2041,1826,2758,1959,5890,2124,781,2290,359,107,108,109,110,508,111,3925,2008,2009,115,426,427,1960,1961,10160,307,9,123,311,125,312,341,1306,7693,6],"aiwire":[31028],"_links":{"self":[{"href":"https:\/\/platoai.gbaglobal.org\/wp-json\/wp\/v2\/platowire\/2543831"}],"collection":[{"href":"https:\/\/platoai.gbaglobal.org\/wp-json\/wp\/v2\/platowire"}],"about":[{"href":"https:\/\/platoai.gbaglobal.org\/wp-json\/wp\/v2\/types\/platowire"}],"author":[{"embeddable":true,"href":"https:\/\/platoai.gbaglobal.org\/wp-json\/wp\/v2\/users\/2"}],"version-history":[{"count":0,"href":"https:\/\/platoai.gbaglobal.org\/wp-json\/wp\/v2\/platowire\/2543831\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/platoai.gbaglobal.org\/wp-json\/wp\/v2\/media\/2527029"}],"wp:attachment":[{"href":"https:\/\/platoai.gbaglobal.org\/wp-json\/wp\/v2\/media?parent=2543831"}],"wp:term":[{"taxonomy":"aiwire-tag","embeddable":true,"href":"https:\/\/platoai.gbaglobal.org\/wp-json\/wp\/v2\/aiwire-tag?post=2543831"},{"taxonomy":"aiwire","embeddable":true,"href":"https:\/\/platoai.gbaglobal.org\/wp-json\/wp\/v2\/aiwire?post=2543831"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}